Phase 1 study on SAR443122 bioavailability and food effect in healthy adults

2025-521073-13-00 Protocol BDR17182 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 11 Jun 2025 · End 25 Jul 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol BDR17182

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 15
Countries 1
Sites 1

Colitis ulcerative

Key facts

Sponsor
Sanofi-Aventis Recherche & Developpement
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
11 Jun 2025 → 25 Jul 2025
Decision date (initial)
2025-06-06
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2025-521073-13-00
WHO UTN
U1111-1315-4506

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Colitis ulcerative

VersionLevelCodeTermSystem organ class
20.0 PT 10009900 Colitis ulcerative 100000004856

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Sanofi-Aventis Recherche & Developpement

Sponsor organisation
Sanofi-Aventis Recherche & Developpement
Address
82 Avenue Raspail
City
Gentilly
Postcode
94250
Country
France

Scientific contact point

Organisation
Sanofi-Aventis Recherche & Developpement
Contact name
Sanofi-Aventis Recherche & Developpement

Public contact point

Organisation
Sanofi-Aventis Recherche & Developpement
Contact name
Sanofi-Aventis Recherche & Developpement

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 15 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2025-06-11 2025-07-25 2025-06-13 2025-06-13

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-04-22 Netherlands Acceptable
2025-06-04
2025-06-06
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-07-21 Netherlands Acceptable
2025-06-04
2025-07-21